Saturday, May 17, 2008

> IVD Technology

 

Current Editorial Focus


Detection Technologies

Electro-chemical detection-based DNA microarrays

Developing a multiplexed genotyping system for clinical diagnostic and pharmacogenetic testing.

Processing Technologies

Centrifugal microfluidic platforms for rapid IVDs

Exploring the challenges and advantages of implementing microfluidics into IVD devices.

Assay Development

Detecting metabolic changes in diabetes mellitus

Fully understanding metabolic disturbances of diabetes mellitus requires measurement of glutamine synthetase activity.

Latest Industry News

Final Thoughts

Improving IVD product development processes

by Dan Olivier and Marta Chase

The IVD industry is rapidly evolving. Technology advances are visible in enhanced hardware performance, increased software functionality, and more sophisticated technological knowledge of the cause of diseases. Expanding regulatory requirements are seen in increasingly complex submission requirements for foreign markets. To keep pace with these changes, IVD manufacturers must continuously refine development plans and enhance development and manufacturing processes.

To stay competitive, manufacturers must continuously strive to shorten their new product development cycles and reduce manufacturing costs while achieving excellent customer service. The companies that have been successful with these methods focus on continuous improvement based on their experience, customer feedback, and internal measures.
read more...




In Person

with

Randy White, PhD
Chief Executive Officer
Adnavance Technologies Inc.


Evolving detection technology methods

High sensitivity and specificity, along with cost reduction, often determine IVD manufacturers’ goals in detection technology development and assay production. As a result, the industry has been slow to adopt any new diagnostic technology that has yet to prove itself commercially. However, in order to increase detection limits and improve sensitivity, developers must be willing to explore alternative methods beyond fluorescence and other light amplification technologies.

To learn more about market stratification and open architecture for microarrays and other IVD products, IVD Technology editor Richard Park spoke with Randy White, chief executive officer of Adnavance Technologies Inc. (Vancouver). In this interview, White shares his views on where he thinks detection platform development is headed and the limits of light amplification. He also discusses metallized DNA, the expectations of molecular diagnostics, and the advantages of strategic partnerships.

Click here to read the interview.